J Cebrecos

Curriculum vitae

Jesús Cebrecos Pérez obtained his Medical Degree (MD) at the University of Barcelona, and his Medicine Specialty Training in Clinical Pharmacology at Hospital Vall d’Hebrón in Barcelona, Spain. Since 2011 is  member of the Clinical Development Department at ESTEVE Pharma (Headquarters in Barcelona, Spain); where he leads, oversee, or provide support in different therapeutics areas, including acute and chronic pain. Previously (1992-2003) he worked at different Medical and Clinical positions at Pfizer. In 2003-2011 he has been the Clinical Studies Director/Phase 1 Clinical Trials Unit Head , and Principal Investigator in several Phase I clinical trials (including first-in-human with new molecular entities) at laboratorio Dr. Echevarne (Barcelona, Spain). He is a former member of a Ethic’s Committee (CEIC-CIMA), former member of different professional associations (including IASP), and current member of the Spanish Society of Clinical Pharmacology(SEFC).

Declaration of Interest

None

The 5 most important personal publication

Richard Langford, Cesar Margarit, Adelaida Morte, Jesús Cebrecos, Mariano Sust, Esther Ortiz, José María Giménez-Arnau & Oscar de Leon-Casasola (2024) Co-crystal of tramadol–celecoxib (CTC) for acute moderate-to-severe pain, Current Medical Research and Opinion, DOI: 10.1080/03007995.2023.2276118

Viscusi ER, de Leon-Casasola O, Cebrecos J, Jacobs A, Morte A, Ortiz E, Sust M, Vaqué A, Gottlieb I, Daniels S, Gimbel JS, Muse D, Winkle P, Kuss ME, Videla S, Gascón N, Plata-Salamán C. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: A phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023 Jan;23(1):8-22. doi: 10.1111/papr.13136. Epub 2022 Jul 8. PMID: 35686380; PMCID: PMC10084286

Cebrecos J., Carlson J. D., Encina G., Lahjou M., Sans A., Sust M., Vaque A., Morte A., Gascon N., & Plata-Salaman C. (2021). Celecoxib-tramadol co-crystal: A randomized 4-way crossover comparative bioavailability study. Clin Ther, 43, 1051–1065. https://doi.org/10.1016/j.clinthera.2021.04.00.

Langford R, Morte A, Sust M, Cebrecos J, Vaqué A, Ortiz E, Fettiplace J, Adeyemi S, Raba G, But-Husaim L, Gascón N, Plata-Salamán C. Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: A randomized, double-blind, phase 3 trial (STARDOM2). Eur J Pain. 2022 Nov;26(10):2083-2096. doi: 10.1002/ejp.2021. Epub 2022 Sep 24. PMID: 35974668; PMCID: PMC9826359.

Langford, R., Pogatzki-Zahn, E.M., Morte, A. et al. Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1). Adv Ther 41, 1025–1045 (2024). https://doi.org/10.1007/s12325-023-02744-2